Wockhardt posts Q3 net profit at Rs. 20 Cr
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
TFOS is indicated for the treatment of pulmonary arterial hypertension
He has over 23 years of experience across sectors
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Plans underway to expand screening capacity by 50% for greater accessibility
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Cancer cases in India estimated to reach 1.57 million in 2025
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Subscribe To Our Newsletter & Stay Updated